AI-aided drug developer company Hoth Therapeutics has entered a strategic partnership with IT and software solutions provider Wise Systems International to leverage AI-based technology for drug discovery.
The collaboration includes Hoth’s access to NVIDIA's BioNeMo AI platform, which can help build and integrate GenAI applications across the entire drug discovery pipeline. With Wise's help, the company aims to further its ongoing pipeline and discover novel therapeutics.
Hoth Therapeutics is a biopharmaceutical company that develops therapies for unmet medical needs. The company's pipeline includes HT-001, a topical treatment in Phase II clinical trials for rash and skin disorders associated with cancer therapies, HT-KIT for mast-cell derived cancers and anaphylaxis, HT-TBI for traumatic brain injury and ischemic stroke, and HT-ALZ for Alzheimer’s disease.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.